BridgeMD
CARotid plaqUe StabilizatiOn and regression with evolocumab
EU CTIS ID: 2024-518566-27-00
What this study is testing
evaluate the superiority of evolocumab in addition to ongoing LLT compared to LLT alone with regards to: a) morphological stabilization of the carotid plaque at 6 months, defined as regression of the ulcerations and "soft" components and obtaining a regular morphology of the plaque with prevalence of fibrous atheroma (type III and IV), evaluated with DUS and/or MRI, or CT b) regression of the carotid plaque at 12 months, defined as reduction in the extent of stenosis and PSV of at least 5% compared to baseline values.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- asymptomatic patients with carotid stenosis mono or bilateral magnitude ≥50% and LDL-C values ≥100 mg/dL despite maximal LLT...
You likely can't join if
- age <18 years, known intolerance to evolocumab, previous or current therapy with PCSK9 inhibitors, previous stroke or TIA, total carotid occlusion, non-subscription of informed consent
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.